Results 71 to 80 of about 19,009 (196)

Indirect comparison of azacitidine and decitabine for the therapy of elderly patients with acute myeloid leukemia: a systematic review and network meta-analysis

open access: yesExperimental Hematology & Oncology, 2020
Background The DNA hypomethylating agents (HMAs) decitabine and azacitidine have been widely used in the management of elderly patients with acute myeloid leukemia (AML). However, no direct clinical trials have been carried out to compare the two agents.
Bingbing Wen   +3 more
doaj   +1 more source

Advances in the Role of Chemokines in Microwave Ablation‐Based Combinatorial Immunotherapy

open access: yesCancer Science, EarlyView.
MWA can initiate antitumor immunity through tumor antigen release and innate immune activation, but iMWA may instead promote an immunosuppressive microenvironment. Combining MWA with immunotherapeutic strategies offers a promising approach to enhance systemic immunity and suppress residual and distant tumors.
Ruijie An, Ningning He, Wendong Gu
wiley   +1 more source

The effect of decitabine on megakaryocyte maturation and platelet release

open access: yes, 2011
SummaryThrombocytopenia is a common feature of myelodysplastic syndromes (MDS). 5-aza-2’-deoxycytidine (decitabine) has been used to treat MDS with an approximately 20% response rate in thrombocytopenia. However, the mechanism of how decitabine increases
Zanhua Yi   +3 more
core   +1 more source

Venetoclax in association with decitabine as effective bridge to transplant in a case of relapsed early T‐cell lymphoblastic leukemia

open access: yesClinical Case Reports, 2020
A case of an early‐relapsed high‐risk T‐ALL with high BCL‐2 expression on leukemic blasts was successfully treated with decitabine and venetoclax, achieving a CR. We suggest decitabine and venetoclax should be synergistic in BCL2‐positive ALL.
Elisabetta Zappone   +8 more
doaj   +1 more source

Guillain–Barre Syndrome With Cytomegalovirus Infection After Allogeneic Hematopoietic Stem Cell Transplantation

open access: yes
The Kaohsiung Journal of Medical Sciences, EarlyView.
Chin‐Mu Hsu   +3 more
wiley   +1 more source

PANoptosis in the pathogenesis of myelodysplastic syndromes

open access: yesMolecular Oncology, Volume 20, Issue 11, Page 2584-2610, November 2026.
PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla   +4 more
wiley   +1 more source

Eltrombopag during induction chemotherapy in older patients with newly diagnosed acute myeloid leukemia is safe and reduces platelet transfusion requirements: The EPAG‐2015 French Innovative Leukemia Organization phase 2 randomized trial

open access: yesCancer, Volume 132, Issue 21, 1 November 2026.
Abstract Background Elderly patients with acute myeloid leukemia (AML) treated with intensive chemotherapy are at risk of developing thrombopenia, which requires platelet transfusions. It would be interesting to provide them with thrombopoietin receptor agonists such as eltrombopag.
Arnaud Pigneux   +24 more
wiley   +1 more source

The type of DNA damage response after decitabine treatment depends on the level of DNMT activity

open access: yesLife Science Alliance
Chromatin-centred proteomics study in stem cells with different DNMT expression levels and activities reveals that decitabine invokes different DNA damage responses depending on the amount of the induced DNA-DNMT crosslinks.
Tina Aumer   +9 more
doaj   +1 more source

Epigenetic silencing of PDLIM4 promotes colorectal cancer by impairing BTF3 autophagic degradation and activating PI3K/Akt signalling

open access: yesClinical and Translational Medicine, Volume 16, Issue 11, November 2026.
• DNMT3A‐mediated PDLIM4 promoter hypermethylation is an early event in colorectal tumorigenesis. • Restoring PDLIM4 suppresses CRC proliferation and stemness while promoting apoptosis in vitro and in vivo. • PDLIM4 promotes the autophagic‐lysosomal degradation of BTF3 and restrains PI3K/Akt signalling.
Jiaxing Wang   +10 more
wiley   +1 more source

Low-Dose Decitabine-Based Chemoimmunotherapy for Patients with Refractory Advanced Solid Tumors: A Phase I/II Report

open access: yesJournal of Immunology Research, 2014
Aberrant DNA methylation is one of the main drivers of tumor initiation and progression. The reversibility of methylation modulation makes it an attractive target for novel anticancer therapies.
Hui Fan   +15 more
doaj   +1 more source

Home - About - Disclaimer - Privacy